KRAS and colorectal cancer: Consistent with finding from a genome-wide RNA interference (RNAi) screen which identified that PLK1 inhibition is synthetic lethal with KRAS mutation,276 onvansertib showed a biased cytotoxicity to cells carrying KRAS mutation compared to wildtype isogenic.277 As a result, onvansertib is explored in a combination trial with folinic acid, 5-fluorouracil, and irinotecan (FOLFIRI) and bevacizumab (a VEGFR antibody) for treatment of 2nd line KRAS mutant colorectal cancer patients.